Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. (CRBP) on April 10, 2024. The filing discloses the approval and execution of amended and restated employment agreements with the Company's Chief Executive Officer, Yuval Cohen, Ph.D., and Chief Financial Officer, Sean Moran, effective April 10, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
The Board approved new two-year employment agreements for the CEO and CFO. Key terms include:
- Yuval Cohen (CEO):
- Annual Base Salary: $622,804.
- Target Annual Bonus: Up to 60% of base salary.
- Severance (Standard): 12 months of base salary plus COBRA coverage if terminated without cause or for good reason.
- Severance (Change in Control): 24 months of base salary, COBRA coverage, accelerated equity vesting, and 2x target bonus.
- Non-compete: 6 months post-employment (subject to severance conditions).
- Sean Moran (CFO):
- Annual Base Salary: $463,455.
- Target Annual Bonus: Up to 40% of base salary.
- Severance (Standard): 12 months of base salary plus COBRA coverage if terminated without cause or for good reason.
- Severance (Change in Control): 18 months of base salary, COBRA coverage, accelerated equity vesting, and 1x target bonus.
- Non-compete: 6 months post-employment (subject to severance conditions).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of operational risks. The primary contingency noted is the potential reduction of severance payments under Internal Revenue Code Section 4999 (excise tax) to ensure the executive is in a better after-tax position.
Investor Verification Checklist
- Verify the total potential cash and equity liability associated with the "Change in Control" severance provisions for both executives.
- Review the attached Exhibits 10.1 and 10.2 for the full legal text of the employment agreements.
- Confirm the current status of the Company's cash reserves to assess the ability to fund potential severance obligations.
- Check for any recent changes in the Company's equity incentive plans referenced in the agreements.